Matinas BioPharma

$0.86
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.0585 (+7.29%) Today
-$0.0009 (-0.10%) As of 5:06 PM EST after-hours

Why Robinhood?

You can buy or sell MTNB and other stocks, options, and ETFs commission-free!

About MTNB

Matinas BioPharma Holdings, Inc., also called Matinas BioPharma, is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B, and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded by Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ. The listed name for MTNB is Matinas BioPharma Holdings, Inc.

CEO
Jerome D. Jabbour
Employees
21
Headquarters
Bedminster, New Jersey
Founded
2013
Market Cap
171.53M
Price-Earnings Ratio
Dividend Yield
Average Volume
1.85M
High Today
$0.88
Low Today
$0.8202
Open Price
$0.8299
Volume
2.94M
52 Week High
$2.49
52 Week Low
$0.49

Collections

MTNB Earnings

-$0.04
-$0.03
-$0.01
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 8, Pre-Market

You May Also Like